Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemo-hypofractionated Radiotherapy Plus PD-1 Antibody (Tislelizumab) in Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05941481 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.

NCT NCT05941481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05941481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemo-hypofractionated Radiotherapy Plus PD-1 Antibody (Tislelizumab) in Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Jiangsu Cancer Institute & Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2023
Completion date
June 20, 2026
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or gastroesophageal junction adenocarcinoma